BioSpace News Archive

Sirtex Medical (“Sirtex”) , a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareholder, China Grand Pharmaceutical and Healthca

On the heels of its recent US launch , Echolight Medical announces the hiring of several industry heavyweights, not only in radiology but specifically in point-of-care service. Seattle -based Gina

RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new collaborations follow recently announced collaborations with European and Canadian manufacturers U.S. Phase 2 study fully enrolled - top-line data expected in the coming weeks; parallel global Phase 2/3 study more than 50% enrolled - top-line data expected Q1/2021

Projects will support health and law professionals, families, and children to recognize the signs and prevent family violence

RedHawk Holdings Corp. (OTC: SNDD) (“RedHawk” or the “Company”), a diversified holding company primarily engaged in sales and distribution of medical devices, announced today that it has completed the re-design of the SANDD Pro™, the Company’s needle inc

LifeLabs is pleased to announce the launch of a new virtual care offering on its customer portal in Ontario.

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November 25, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

PostEra, a biotechnology company offering medicinal chemistry powered by machine learning, today announced a collaboration with NeuroLucent, a Chicago-based company focused on developing novel treatments for Alzheimer’s disease and other dementias.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, reports that its lead drug candidate, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes, has been featured on multiple television news outlets.